期刊文献+

抗凝治疗对永久性下腔静脉滤器置入术后滤器通畅率的影响 被引量:5

Efficacy of anticoagulation on patency post-permanent inferior vena cavai filter placements
原文传递
导出
摘要 目的研究抗凝治疗对永久性下腔静脉滤器黄入术后滤器通畅率的影响。方法回顾性分析2001年12月至2007年12月138例因下肢深静脉血栓形成置入永久性下腔静脉滤器的患者。男性75例,女性63例,平均年龄65岁。随访其口服华法林时间和下腔静脉滤器的通畅状况。按口服华法林的长短分为未抗凝组(n=41)、抗凝A组(口服华法林≤6个月,n=20)和抗凝B组(口服华法林〉6个月,n=77)。X^2检验比较各组患者的滤器闭塞率,Kaplan-Meier生存分析比较各组的平均滤器通畅时间和1、3年滤器累计通畅率,Log-rank法进行显著性检验。结果本研究死亡16例,其中1例患者死于肺栓塞。确定为终点事件者为19例(13.8%)。未抗凝组、抗凝A组和抗凝B组之间滤器通畅率(87.8%、75.0%和88.3%)差异无统计学意义(P=0.288)。三组滤器通畅时间和1、3年的滤器累计通畅率(87.1%、80.0%、94.8%和87.1%、74.3%、85.4%)差异亦无统计学意义(P=0.227).结论抗凝治疗对滤器晋入术后滤器涌畅率的根高沿右明显影响. Objective To discuss the efficacy of anticoagulation on patency post-permanent inferior vena caval filter (IVCF) placements. Methods The patients with deep vein thrombosis (DVT) of the lower extremity who were accepted permanent IVCF placement from December 2001 to December 2007 were reviewed retrospectively. Data on vital status, filter thromboembolism, anticoagulation time, and so on were obtained through follow-up. One hundred and thirty eight patients (75 male and 63 female) with a mean age of 65 years were enrolled in the study. All the patients were divided into non-anticoagulation group, anticoagulation group A with taking warfarin less than 6 months, or anticoagulation group B with taking warfarin more than 6 months.X^2 test, t test, Kaplan-Meier survival curve, Log-rank test were used for statistics analysis. Results Sixteen patients died, and 1 of them died of pulmonary embolism. Including the 1 patient mentioned before, there were 19 patients ( 13.8% ) suffered from filter thromboembolism. Upon X^2 test, there were no significant differences (P = 0. 288) on the patency rates between non-anticoagulation,anticoagulation group A and anticoagulation group B (87.8%, 75.0% , and 88.3% respectively). Upon Kaplan-Meier survival analysis, there were still no significant differences (P =0. 227) on the mean patency time and the cumulate rates of patency at the 1st or 3rd year between the 3 groups (87. 1%, 80. 0% , 94. 8% and 87. 1%, 74. 3%, 85.4% respectively). Conclusion Anticoagulation has no efficacy on patency post-permannet IVCF placements.
出处 《中华外科杂志》 CAS CSCD 北大核心 2010年第2期93-95,共3页 Chinese Journal of Surgery
关键词 静脉血栓形成 腔静脉滤器 抗凝药 Venous thrombosis Vena eava filters Anticoagulants
  • 相关文献

参考文献11

  • 1Athanasoulis CA, Kaufman JA, Halpern EF, et al. Inferior vena eaval filters : review of a 26-year single-center clinical experience. Radiology ,2000,216:54-66.
  • 2寇镭,吴庆华,邓洪儒,陈忠,杨宝钟.永久性下腔静脉滤器置入术预防肺栓塞71例经验[J].中华普通外科杂志,2004,19(5):263-265. 被引量:29
  • 3栾景源,董国祥,赵军,李天润,康林.下腔静脉滤器继发血栓形成[J].中国微创外科杂志,2005,5(3):226-228. 被引量:19
  • 4Shokoohi H, Smith J, Holmes A, et al. Bilateral compartment syndrome as a result of inferior vena cava filter thrombosis. Ann Emerg Med ,2008,52 : 104-107.
  • 5Crochet DP, Brunel P, Trogrlic S, et al. Long-term follow-up of Vena Tech-LGM filter: predictors and frequency of caval occlusion. J Vascular lnterv Radiol, 1999,10 : 137-142.
  • 6Greenfield LJ,Proctor MC. Recurrent thromboembolism in patients with vena cava filters. J Vasc Surg,2001,33 :510-514.
  • 7曹满瑞,陆普选,李莹,徐坚民.滤器预防肺栓塞:滤器血栓及相关因素分析[J].中国医学影像技术,2004,20(1):82-84. 被引量:15
  • 8Ray CE Jr, Prochazka A. The need for anticoagulation following inferior vena cava filter placement: systematic review. Cardiovasc Intervent Radio1,2008,31:316-324.
  • 9PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREP1C (Prevention du Risque d' Embolie Pulmonaire par Interruption Cave) randomized study. Circulation, 2005,112:416422.
  • 10牛鹿原,张福先,梁刚柱,张欢,温志军.腔静脉滤器临床应用现状[J].中华外科杂志,2008,46(10):793-795. 被引量:4

二级参考文献49

  • 1Bell WR, Simon TL. Current status of pulmonary thromboembolic disease : pathophysiology, diagnosis, prevention, and treatment. Am Heart J, 1982, 103:239-262.
  • 2Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet, 1999,353 : 1386-1389.
  • 3Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med,2004 ,350:2257-2264.
  • 4Greenfield LJ, Michna BA. Twelve-year clinical experience with the Greenfield vena caval filter. Surgery, 1988,104 : 706-712.
  • 5Stein PD, Kayali F, Olson RE. Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med,200d, 164: 1541- 1545.
  • 6Jaff MR, Goldhaber SZ, Tapson VF. High utilization rate of vena cava filters in deep vein thrombosis. Thromb Haemost, 2005,93 : 1117-1119.
  • 7Cook A, Shackford S, Osier T, et al. Use of vena cava filters in pediatric trauma patients: data from the National Trauma Data Bank. J Trauma,2005,59:1114-1120.
  • 8Athanasoulis CA, Kaufman JA, Halpem EF, et al. Inferior vena caval fibers: review of a 26-year single-center clinical experience. Radiology ,2000,216:54-66.
  • 9van Marle IC, Veller M, Scholz L, et al. Guidelines for the endovascular treatment of peripheral vascular disease. S Afr Med J,2005,95 (TPt2) :519-526.
  • 10Dovrish Z, Hadary R, Blickstein D, et al. Retrospective analysis of the use of inferior vena cava filters in routine hospital practice. Postgrad Med J ,2006,82 : 150-153.

共引文献60

同被引文献76

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部